Cirrhosis is diagnosed through a combination of blood tests, imaging, physical examination, and sometimes liver biopsy. No single test confirms it on its own. Instead, doctors piece together findings from several sources to determine whether the liver has developed the widespread scarring that defines cirrhosis, and if so, how severe it is.
Physical Signs Your Doctor Looks For
A physical exam can reveal visible clues that point toward cirrhosis, though many people with early-stage disease look completely normal. The signs that do appear are largely driven by the liver’s inability to properly process hormones, proteins, and waste products.
Spider nevi are one of the more distinctive findings: small red spots with tiny blood vessels radiating outward like spider legs, typically on the upper chest, face, and arms. They develop because a damaged liver can’t break down estrogen efficiently, leading to a buildup that triggers the growth of small blood vessels. The same hormonal imbalance causes palmar erythema, a reddening of the palms that’s especially noticeable at the base of the thumb and little finger. In men, excess estrogen can also cause breast tissue enlargement and shrinking of the testes.
Jaundice, the yellowing of the skin and whites of the eyes, appears when bilirubin (a waste product from broken-down red blood cells) accumulates in the blood because the liver can no longer clear it. This tends to show up in more advanced disease. Other findings include an enlarged or shrunken liver that feels hard or lumpy, a swollen spleen, visible veins on the abdomen, and fluid buildup in the belly.
Blood Tests That Flag Liver Damage
Routine blood work often provides the first objective evidence that something is wrong with the liver. Several markers shift in characteristic ways as cirrhosis develops:
- Platelet count below 150,000: A falling platelet count is one of the earliest and most reliable blood markers. The scarred liver traps platelets and reduces production of the hormone that stimulates their growth.
- Albumin below 3.5 g/dL: Albumin is a protein made exclusively by the liver. When liver function drops, albumin production falls with it.
- Bilirubin above 1.5 mg/dL: Elevated bilirubin reflects the liver’s declining ability to process waste, though this finding alone is nonspecific.
- AST higher than ALT: In most liver diseases, these two enzymes rise together, but in cirrhosis (especially alcohol-related), AST tends to exceed ALT. This reversal of the usual pattern is a useful diagnostic hint.
- Prolonged clotting time (elevated INR): The liver produces most of the body’s clotting factors. As cirrhosis progresses, blood takes longer to clot.
None of these results alone proves cirrhosis. A low platelet count has many other causes, and liver enzymes can be normal even with significant scarring. But when several of these markers appear together, they form a pattern that strongly suggests cirrhosis and prompts further testing.
Non-Invasive Scoring Tools
Doctors now use simple formulas that combine routine blood work into a single score to estimate how much scarring is present. The most widely used is the FIB-4 index, which plugs your age, platelet count, AST, and ALT into a calculation. A FIB-4 score below 1.45 effectively rules out advanced fibrosis about 90% of the time. A score above 3.25 is highly specific for advanced fibrosis or cirrhosis, with 97% specificity. Scores between those two values fall into a gray zone that usually requires further evaluation with imaging or biopsy.
These scoring tools are valuable because they require nothing beyond a standard blood draw. They’re often the first step in deciding whether someone needs more advanced testing.
Imaging: Ultrasound and Elastography
A standard abdominal ultrasound can show structural changes that suggest cirrhosis: a bumpy, irregular liver surface instead of a smooth one, shrinkage of certain parts of the liver while other parts enlarge (particularly the caudate lobe), and the appearance of regenerative nodules where the liver has tried to repair itself. Secondary signs of portal hypertension, the dangerous backup of blood pressure in the liver’s circulation, may also be visible. These include an enlarged spleen, fluid in the abdomen, and dilated veins around the stomach and esophagus.
CT and MRI scans show these same features in greater detail and are especially useful for evaluating complications or screening for liver cancer, which cirrhosis significantly increases the risk of.
Transient elastography (often called by the brand name FibroScan) has become a cornerstone of non-invasive diagnosis. This painless test uses a probe pressed against the skin to send a vibration wave through the liver and measure how stiff the tissue is. Healthy liver is soft; scarred liver is rigid. Stiffness is reported in kilopascals (kPa). A reading above 12.5 kPa suggests severe fibrosis, and above 17.6 kPa strongly indicates cirrhosis, with a positive predictive value of at least 90%. The median stiffness in confirmed cirrhosis patients is around 31 kPa, though values range widely. Alcohol-related cirrhosis tends to produce higher readings (median 52.4 kPa) compared to viral hepatitis-related cirrhosis (median 23 kPa), partly because of inflammation and swelling that add to the stiffness measurement.
When Liver Biopsy Is Still Needed
Liver biopsy was once the only way to definitively diagnose cirrhosis. A needle is inserted through the skin to extract a small core of liver tissue, which is then examined under a microscope for the characteristic pattern of widespread scarring and distorted architecture. With the accuracy of modern blood tests and elastography, biopsy is no longer routine for straightforward cases.
It remains essential, however, in specific situations where the cause or nature of the liver disease is unclear. If a doctor suspects autoimmune hepatitis but the patient is also obese (making fatty liver disease equally plausible), biopsy can distinguish between the two. It’s critical for diagnosing Wilson disease, a genetic copper-storage condition that mimics many other liver diseases. In patients who have received a liver transplant, biopsy is often the only reliable way to tell whether abnormal blood tests reflect organ rejection, a returning infection, or a blood vessel problem. It also helps in overlap syndromes where two liver conditions appear to coexist.
Staging Severity With the Child-Pugh Score
Once cirrhosis is confirmed, the next step is determining how well the liver is still functioning. The Child-Pugh scoring system does this by rating five factors on a scale of 1 to 3 points each: bilirubin level, albumin level, how quickly blood clots (measured by INR or prothrombin time), the presence and severity of ascites (fluid in the abdomen), and the presence and severity of hepatic encephalopathy (confusion and cognitive changes caused by toxin buildup).
The total score places patients into one of three classes:
- Class A (5 to 6 points): Well-compensated cirrhosis. The liver is damaged but still handling its essential jobs reasonably well.
- Class B (7 to 9 points): Significant functional compromise. Symptoms and complications are present but manageable.
- Class C (10 to 15 points): Decompensated cirrhosis. The liver is failing, and transplant evaluation is typically warranted.
A related score called MELD-Na is used specifically to prioritize patients on the liver transplant waiting list. It incorporates creatinine (a measure of kidney function), bilirubin, INR, sodium, albumin, age, and sex into a calculation that predicts short-term survival. Higher scores indicate more urgent need for transplant.
Compensated vs. Decompensated Cirrhosis
The most important clinical distinction in cirrhosis is whether the disease is compensated or decompensated. In compensated cirrhosis, the liver is scarred but still functioning well enough that the person may have few or no symptoms. Many people live years in this stage without knowing they have cirrhosis.
The transition to decompensated cirrhosis is defined by the appearance of specific complications: ascites (fluid accumulation in the abdomen), variceal hemorrhage (bleeding from swollen veins in the esophagus or stomach), hepatic encephalopathy (confusion, personality changes, or drowsiness caused by toxins the liver can no longer filter), or jaundice. The development of any one of these marks a major turning point, as the prognosis worsens significantly once decompensation occurs.
Measuring Portal Hypertension
Portal hypertension, the buildup of pressure in the vein that carries blood to the liver, drives most of the dangerous complications of cirrhosis. It’s measured by a procedure called hepatic venous pressure gradient (HVPG), where a catheter is threaded through a neck vein into the liver’s blood vessels to take pressure readings. Normal pressure is 5 mmHg or less. A reading of 6 mmHg or higher indicates portal hypertension, though pressures between 5 and 9 mmHg are considered subclinical, meaning they haven’t yet caused problems.
At 10 mmHg, portal hypertension becomes clinically significant, meaning varices can start forming and complications become a real threat. At 12 mmHg or above, the risk of ascites, bleeding from varices, and encephalopathy rises sharply. This measurement isn’t done routinely in every patient, but it’s valuable for guiding treatment decisions and predicting which patients are most likely to develop complications.